Marty Makary: “We're saying basically we think all biosimilars should be…”

“First, on the final guidance, I would say three to six months. On the interchangeability, it's very complicated because we have the opportunity at the FDA to designate a biosimilar as interchangeable. We're saying basically we think all biosimilars should be interchangeable. And then states have their own rules on whether or not patients need to be consented or not for substitution. So we're planting a flag saying we want interchangeability, we promote it, we encourage it.” (29:33–29:39)

This is an excerpt from a raw transcript. The assertions have not been audited or verified. Tap the video to view the source footage and understand the context.